{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T12:04:28Z","timestamp":1791288268309,"version":"4.3.0"},"reference-count":36,"publisher":"Spandidos Publications","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,4]]},"DOI":"10.3892\/ol.2013.1146","type":"journal-article","created":{"date-parts":[[2013,1,22]],"date-time":"2013-01-22T09:54:23Z","timestamp":1358848463000},"page":"1140-1148","source":"Crossref","is-referenced-by-count":10,"title":["A study of docetaxel weekly or every three weeks in combination with carboplatin as first line chemotherapy in epithelial ovarian cancer: Hematological and non-hematological toxicity profiles"],"prefix":"10.3892","volume":"5","author":[{"given":"BENGT","family":"SORBE","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MARIANNE","family":"GRAFLUND","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"LISA","family":"NYGREN","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"GY\u00d6RGY","family":"HORVATH","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2249","published-online":{"date-parts":[[2013,1,22]]},"reference":[{"key":"key20180108092546_b1-ol-05-04-1140","volume-title":"GLOBOCAN 2008, Cancer incidence and mortality worldwide: IARC CaseBase No. 10","author":"Ferlay","year":"2010"},{"key":"key20180108092546_b2-ol-05-04-1140","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1056\/NEJM199601043340101","article-title":"Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer","volume":"334","author":"McGuire","year":"1996","journal-title":"N Engl J Med"},{"key":"key20180108092546_b3-ol-05-04-1140","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/S0090-8258(03)00337-8","article-title":"Gynecologic Oncology Group Protocol GOG 182-ICON5. Clinical trials of newer regimens for treating ovarian cancer: the rationale for Gynecologic Oncology Group Protocol GOG 182-ICON5","volume":"90","author":"Copeland","year":"2003","journal-title":"Gynecol Oncol"},{"key":"key20180108092546_b4-ol-05-04-1140","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.ygyno.2009.04.008","article-title":"Combined weekly carboplatin and paclitaxel as primary treatment of advanced epithelial ovarian carcinoma","volume":"114","author":"Safra","year":"2009","journal-title":"Gynecol Oncol"},{"key":"key20180108092546_b5-ol-05-04-1140","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s00280-007-0466-z","article-title":"Weekly paclitaxel and carboplatin (PC-W) for patients with primary advanced ovarian cancer: results of a multicenter phase-II study of the NOGGO","volume":"61","author":"Sehouli","year":"2008","journal-title":"Cancer Chemother Pharmacol"},{"key":"key20180108092546_b6-ol-05-04-1140","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1016\/S0140-6736(09)61157-0","article-title":"Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial","volume":"374","author":"Katsumata","year":"2009","journal-title":"Lancet"},{"key":"key20180108092546_b7-ol-05-04-1140","first-page":"73","article-title":"Docetaxel in the treatment of ovarian cancer","volume":"16","author":"Kavanagh","year":"2002","journal-title":"Oncology"},{"key":"key20180108092546_b8-ol-05-04-1140","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1038\/sj.bjc.6601495","article-title":"Docetaxel: an alternative taxane in ovarian cancer","volume":"89","author":"Katsumata","year":"2003","journal-title":"Br J Cancer"},{"key":"key20180108092546_b9-ol-05-04-1140","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1093\/jnci\/djh323","article-title":"Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma","volume":"96","author":"Vasey","year":"2004","journal-title":"J Natl Cancer Inst"},{"key":"key20180108092546_b10-ol-05-04-1140","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.ygyno.2006.12.018","article-title":"Weekly docetaxel and carboplatin for recurrent ovarian and peritoneal cancer: a phase II trial","volume":"105","author":"Kushner","year":"2007","journal-title":"Gynecol Oncol"},{"key":"key20180108092546_b11-ol-05-04-1140","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/j.ygyno.2006.10.006","article-title":"Phase II trial of weekly docetaxel for patients with relapsed ovarian cancer who have previously received paclitaxel - ANZGOG 02-01","volume":"104","author":"Tinker","year":"2007","journal-title":"Gynecol Oncol"},{"key":"key20180108092546_b12-ol-05-04-1140","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.ygyno.2009.02.018","article-title":"A phase II study of weekly topotecan and docetaxel in heavily treated patients with recurrent uterine and ovarian cancers","volume":"113","author":"Gupta","year":"2009","journal-title":"Gynecol Oncol"},{"key":"key20180108092546_b13-ol-05-04-1140","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1159\/000224658","article-title":"A feasibility study of weekly docetaxel with capecitabine in ovarian cancer: a promising combination of two active drugs with a potential for synergism","volume":"55","author":"Safra","year":"2009","journal-title":"Chemotherapy"},{"key":"key20180108092546_b14-ol-05-04-1140","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1007\/s10147-003-0351-7","article-title":"Weekly docetaxel for patients with platinum\/paclitaxel\/irinotecan-resistent relapsed ovarian cancer: a phase I study","volume":"8","author":"Terauchi","year":"2003","journal-title":"Int J Clin Oncol"},{"key":"key20180108092546_b15-ol-05-04-1140","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.ygyno.2004.08.028","article-title":"A phase II trial of weekly docetaxel in patients with platinum-resitent epithelial ovarian, primary peritoneal serous cancer, or fallopian tube cancer","volume":"95","author":"Berkenblit","year":"2004","journal-title":"Gynecol Oncol"},{"key":"key20180108092546_b16-ol-05-04-1140","first-page":"299","article-title":"A pilot study of weekly docetaxel therapy for recurrent ovarian cancer, tubal cancer, and primary peritoneal cancer","volume":"6","author":"Komiyama","year":"2005","journal-title":"Eur J Gynaecol Oncol"},{"key":"key20180108092546_b17-ol-05-04-1140","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1097\/IGC.0b013e318234fa3a","article-title":"Phase II study of docetaxel weekly in combination with carboplatin every 3 weeks as first-line chemotherapy in stage IIB to stage IV epithelial ovarian cancer","volume":"22","author":"Sorbe","year":"2012","journal-title":"Int J Gynecol Cancer"},{"key":"key20180108092546_b18-ol-05-04-1140","first-page":"773","article-title":"A phase II study of docetaxel weekly in combination with carboplatin every three weeks as first line chemotherapy in stage IIB-IV epithelial ovarian cancer: neurological toxicity and quality-of-life evaluation","volume":"40","author":"Sorbe","year":"2012","journal-title":"Int J Oncol"},{"key":"key20180108092546_b19-ol-05-04-1140","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1200\/JCO.1989.7.11.1748","article-title":"Carboplatin dosage: prospective evaluation of a simple formula based on renal function","volume":"7","author":"Calvert","year":"1989","journal-title":"J Clin Oncol"},{"key":"key20180108092546_b20-ol-05-04-1140","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1159\/000180580","article-title":"Prediction of creatinine clearance from serum creatinine","volume":"16","author":"Cockcroft","year":"1976","journal-title":"Nephron"},{"key":"key20180108092546_b21-ol-05-04-1140","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/BF00944177","article-title":"Southwest oncology group standard response criteria, endpoint definitions and toxicity criteria","volume":"10","author":"Green","year":"1992","journal-title":"Invest New Drugs"},{"key":"key20180108092546_b22-ol-05-04-1140","doi-asserted-by":"crossref","first-page":"3919","DOI":"10.1158\/1078-0432.CCR-03-0787","article-title":"Use of CA-125 in clinical trial evaluation of new therapeutic drugs for ovarian cancer","volume":"10","author":"Rustin","year":"2004","journal-title":"Clin Cancer Res"},{"key":"key20180108092546_b23-ol-05-04-1140","volume-title":"Common Terminology Criteria for Adverse Events (Version 3.0)","author":"National Institute of Health","year":"2003"},{"key":"key20180108092546_b24-ol-05-04-1140","volume-title":"EORTC QLQ-C30 Scoring Manual","author":"Fayers","year":"2001","edition":"3rd edition"},{"key":"key20180108092546_b25-ol-05-04-1140","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1111\/j.1525-1438.2007.00886.x","article-title":"A phase II study of outpatient first-line paclitaxel, carboplatin, and bevacizumab for advanced-stage epithelial ovarian, peritoneal, and fallopian tube cancer","volume":"17","author":"Micha","year":"2007","journal-title":"Int J Gynecol Cancer"},{"key":"key20180108092546_b26-ol-05-04-1140","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1200\/JCO.2009.22.7900","article-title":"Phase II study of carboplatin, paclitaxel, and bevacizumab with maintenance bevacizumab as first-line chemotherapy for advanced mullerian tumors","volume":"28","author":"Penson","year":"2010","journal-title":"J Clin Oncol"},{"key":"key20180108092546_b27-ol-05-04-1140","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1200\/JCO.2007.11.6699","article-title":"Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840","volume":"26","author":"Seidman","year":"2008","journal-title":"J Clin Oncol"},{"key":"key20180108092546_b28-ol-05-04-1140","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1002\/cncr.11527","article-title":"Blockage of the lacrimal drainage apparatus as a side effect of docetaxel therapy","volume":"98","author":"Esmaeli","year":"2003","journal-title":"Cancer"},{"key":"key20180108092546_b29-ol-05-04-1140","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/S0090-8258(03)00322-6","article-title":"A feasibility study on biweekly administration of docetaxel for patients with recurrent ovarian cancer","volume":"90","author":"Oishi","year":"2003","journal-title":"Gynecol Oncol"},{"key":"key20180108092546_b30-ol-05-04-1140","first-page":"262","article-title":"Paclitaxel-associated subungual pyogenic granuloma: report in a patient with breast cancer receiving paclitaxel and review of drug-induced pyogenic granulomas adjacent and beneath the nail","volume":"11","author":"Paul","year":"2012","journal-title":"J Drugs Dermatol"},{"key":"key20180108092546_b31-ol-05-04-1140","doi-asserted-by":"crossref","first-page":"4595","DOI":"10.1200\/JCO.2004.08.080","article-title":"Quality of life in ovarian cancer patients: Comparison of paclitaxel plus cisplatin, with cyclophosphamide plus cisplatin in randomized study","volume":"22","author":"Bezjak","year":"2004","journal-title":"J Clin Oncol"},{"key":"key20180108092546_b32-ol-05-04-1140","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1002\/cncr.10802","article-title":"Nonneutropenic febrile episodes associated with docetaxel-based chemotherapy in patients with solid tumors","volume":"95","author":"Souglakos","year":"2002","journal-title":"Cancer"},{"key":"key20180108092546_b33-ol-05-04-1140","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2005.02.4067","article-title":"Randomized study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group comparing quality of life in patients with ovarian cancer treated with cisplatin\/paclitaxel versus carboplatin\/paclitaxel","volume":"24","author":"Greimel","year":"2006","journal-title":"J Clin Oncol"},{"key":"key20180108092546_b34-ol-05-04-1140","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1016\/S0959-8049(00)00447-0","article-title":"Reference data for the quality of life questionnaire EORTC QLQ-C30 in the general German population","volume":"37","author":"Schwarz","year":"2001","journal-title":"Eur J Cancer"},{"key":"key20180108092546_b35-ol-05-04-1140","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1188\/04.ONF.615-623","article-title":"Psychometric evaluation of two scales assessing functional status and peripheral neuropathy associated with chemotherapy for ovarian cancer: A Gynecologic Oncology Group study","volume":"31","author":"Almadrones","year":"2004","journal-title":"Oncol Nurs Forum"},{"key":"key20180108092546_b36-ol-05-04-1140","doi-asserted-by":"crossref","first-page":"5605","DOI":"10.1200\/JCO.2005.08.147","article-title":"Quality-of-life comparisons in a randomized trial of interval secondary cytoreduction in advanced ovarian carcinoma: A Gynecologic Oncology Group study","volume":"23","author":"Wenzel","year":"2005","journal-title":"J Clin Oncol"}],"container-title":["Oncology Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/spandidos-publications.com\/10.3892\/ol.2013.1146\/download","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,1,8]],"date-time":"2018-01-08T05:44:47Z","timestamp":1515390287000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.spandidos-publications.com\/10.3892\/ol.2013.1146"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,1,22]]},"references-count":36,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2013,1,22]]},"published-print":{"date-parts":[[2013,4]]}},"alternative-id":["10.3892\/ol.2013.1146"],"URL":"https:\/\/doi.org\/10.3892\/ol.2013.1146","relation":{},"ISSN":["1792-1074","1792-1082"],"issn-type":[{"value":"1792-1074","type":"print"},{"value":"1792-1082","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,1,22]]}}}